To validate our protocol, we performed it on two different cell lines, namely: U2OS, a bone osteosarcoma cell line that elongates telomeres through ALT mechanisms, and HeLa, a telomerase-positive cervical carcinoma cell line. The gene discussed is GPT; the disease is cervical carcinoma.